Snoretox Ltd. has developed a groundbreaking therapeutic approach to address Brachycephalic Obstructive Airways Syndrome (BOAS) and various muscle weakness conditions. Their innovative technology utilizes modified molecules of tetanus toxin, which are designed to function effectively alongside the tetanus vaccine. This novel application allows for muscle toning, contrasting with the muscle-relaxing effects of botulinum toxin used in Botox. The therapeutic products, trademarked as Snoretox for sleep apnea and Tonetox for other applications, target a range of conditions including muscle recovery, sphincter weakness, and neurological disorders, as well as cosmetic muscle toning.

The company has received significant recognition and support for its research and development efforts, including a Break-through Therapy “Barrier to Innovation” Waiver from the FDA's Center for Veterinary Medicine, which underscores the innovative nature of their drug. Additionally, Snoretox has been awarded a $1 million grant from the Medical Research Future Fund to facilitate the translation of their research into clinical applications. Their commitment to improving the quality of life for individuals suffering from muscle weakness is further evidenced by collaborations with various governmental and research institutions, highlighting the potential impact of their therapeutic solutions in both human and veterinary medicine.

Australia

In collaboration with RMIT University, Snoretox is developing the world’s first injectable solution to treat obstructive sleep apnoea and other conditions involving low muscle tone.

Our game-changing technology is based on molecules of tetanus toxin, modified to ensure they work around the tetanus vaccine.

Just as Botox uses tiny amounts of botulinum toxin to relax muscles, our prototype therapeutic uses minute amounts of safe modified tetanus toxin to achieve the opposite effect – muscle toning.

Snoretox

Company Details